CN107449650B - Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling - Google Patents
Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling Download PDFInfo
- Publication number
- CN107449650B CN107449650B CN201710508392.6A CN201710508392A CN107449650B CN 107449650 B CN107449650 B CN 107449650B CN 201710508392 A CN201710508392 A CN 201710508392A CN 107449650 B CN107449650 B CN 107449650B
- Authority
- CN
- China
- Prior art keywords
- solution
- glycan
- glycans
- benzoyl chloride
- maldi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000004445 quantitative analysis Methods 0.000 title claims abstract description 19
- 238000001948 isotopic labelling Methods 0.000 title claims abstract description 8
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 title claims 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 13
- 150000004676 glycans Chemical class 0.000 claims abstract description 13
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 claims abstract description 4
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 12
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 claims description 5
- 238000010586 diagram Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 3
- 150000002337 glycosamines Chemical class 0.000 claims description 3
- 239000012488 sample solution Substances 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 5
- 238000007405 data analysis Methods 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 2
- 238000007344 nucleophilic reaction Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 27
- 238000001212 derivatisation Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010066476 ribonuclease B Proteins 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- -1 glycan ion Chemical class 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 102000013361 fetuin Human genes 0.000 description 2
- 108060002885 fetuin Proteins 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 101800000343 Glycoprotein N Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 238000003981 capillary liquid chromatography Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 description 1
- HNQXDLYBFNWFEE-VHZSLYHRSA-N n-[(2r,3r,4r,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-5-[(2r,3s,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis[[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]oxan-2-yl]oxy-1-oxo-4-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] Chemical compound O([C@H]([C@H](C=O)NC(=O)C)[C@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H](CO[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1[C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O HNQXDLYBFNWFEE-VHZSLYHRSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/38—Diluting, dispersing or mixing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
- G01N27/64—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode using wave or particle radiation to ionise a gas, e.g. in an ionisation chamber
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
技术领域technical field
本发明属于糖蛋白组学分析领域,具体涉及一种基于MALDI-MS及稳定同位素标记的N聚糖快速定量分析方法。The invention belongs to the field of glycoproteomics analysis, and in particular relates to a rapid quantitative analysis method of N-glycans based on MALDI-MS and stable isotope labeling.
背景技术Background technique
基质辅助激光解析电离质谱(MALDI-MS)技术诞生于80年代末期,是一种“软离子”质谱技术,具有样品不易裂解、分子离子峰强、灵敏度高等特点,该技术为分析强极性、热不稳定和难挥发的生物样品提供了新途径,逐渐成为分析蛋白样品、多肽、核酸的首选方法。Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) technology was born in the late 1980s. It is a "soft ion" mass spectrometry technology. It has the characteristics of difficult sample cracking, strong molecular ion peaks and high sensitivity. Thermally unstable and non-volatile biological samples provide a new approach and gradually become the preferred method for the analysis of protein samples, peptides, and nucleic acids.
稳定同位素标记技术主要是利用稳定性同位素及其化合物特性展开的,在自然界中,稳定性同位素及其化合物与相应的普通元素及化合物之间的化学性质和生物性质是相同的,只是具有不同的核物理性质,因此,可以用稳定性同位素作为示踪原子,制成标记化合物(如标记无机盐、标记氨基酸、标记药物、标记蛋白质等)代替相应的非标记化合物。Stable isotope labeling technology is mainly developed by using the characteristics of stable isotopes and their compounds. In nature, stable isotopes and their compounds have the same chemical and biological properties as the corresponding common elements and compounds, but have different Therefore, stable isotopes can be used as tracer atoms to make labeled compounds (such as labeled inorganic salts, labeled amino acids, labeled drugs, labeled proteins, etc.) instead of corresponding non-labeled compounds.
糖基化修饰是一种重要的蛋白质翻译后修饰,且蛋白质的异常糖基化往往与多种疾病相关联,因而急需能够分析寡糖微量变化的特异性检测方法。如今许多分析检测技术都被应用于监测聚糖的变化,如毛细管电泳、液相色谱以及质谱技术,然而这些技术或多或少存在不足,如不同离子化效率导致的样品间的差异性、仪器响应值之间的差异以及内标或外标的缺乏等。此外,虽然一些同位素定量技术也被应用于聚糖定量分析,但是仍存在很多缺点,如冗长的反应时间(10h~18h)、极端反应条件(酸性、高温)所造成的酸性基团的破坏、质谱检测时酸性糖的源后和源内解析等,这些都严重限制了聚糖的定量分析。Glycosylation is an important post-translational modification of proteins, and abnormal glycosylation of proteins is often associated with various diseases. Therefore, specific detection methods that can analyze the trace changes of oligosaccharides are urgently needed. Today, many analytical detection techniques are used to monitor changes in glycans, such as capillary electrophoresis, liquid chromatography, and mass spectrometry. However, these techniques have more or less deficiencies, such as sample-to-sample variability caused by different ionization efficiencies, instrumental Differences between response values and lack of internal or external standards, etc. In addition, although some isotopic quantification techniques have also been applied to the quantitative analysis of glycans, there are still many disadvantages, such as the lengthy reaction time (10h-18h), the destruction of acidic groups caused by extreme reaction conditions (acidity, high temperature), Post-source and in-source resolution of acid sugars in mass spectrometry detection severely limit the quantitative analysis of glycans.
发明内容SUMMARY OF THE INVENTION
针对已有技术中所存在的不足,我们建立了一种快速有效的基于稳定同位素定量聚糖的方法,该方法应用MALDI-MS及稳定同位素标记技术,对N聚糖快速定量分析,实现对中性糖和酸性糖的同时定量分析、降低实验成本、提升实验效率,缩短反应时间,具有医学开发应用价值。In view of the deficiencies in the existing technology, we have established a fast and effective method for quantitative glycan based on stable isotope. Simultaneous quantitative analysis of sexual sugars and acidic sugars, reducing experimental costs, improving experimental efficiency, and shortening reaction time, have medical development and application value.
为了实现本发明的目的,发明人通过大量试验研究和不懈探索,最终获得了如下技术方案:In order to realize the purpose of the present invention, the inventor finally obtained the following technical solutions through a large number of experimental studies and unremitting exploration:
一种基于MALDI-MS及稳定同位素标记的N聚糖快速定量分析方法,该方法包括如下步骤:A method for rapid quantitative analysis of N-glycans based on MALDI-MS and stable isotope labeling, the method comprises the following steps:
(1)微波辅助快速酶切:标准糖蛋白(10ug)或血清(5ul)溶解于20ul 反应溶液中(含有10mM磷酸钠、0.13%的十二烷基硫酸钠、10mM二硫苏糖醇),之后于100℃水浴中煮沸10min,加入2.4ul 10%的NP-40,混匀后再加入0.5ul PNGase F,在微波辅助条件下酶切20min(实验所用微波炉最大输出功率为700W,反应时选用最低档位),使N聚糖以糖胺形式释放。(1) Microwave-assisted rapid digestion: standard glycoprotein (10ug) or serum (5ul) was dissolved in 20ul reaction solution (containing 10mM sodium phosphate, 0.13% sodium dodecyl sulfate, 10mM dithiothreitol), Then boil in a 100°C water bath for 10min, add 2.4ul of 10% NP-40, add 0.5ul of PNGase F after mixing, and digest the enzyme for 20min under microwave-assisted conditions (the maximum output power of the microwave oven used in the experiment is 700W. lowest gear), which releases N-glycans in the form of glycosamines.
(2)步骤(1)所得糖胺与d0/d5-苯甲酰氯(d0代表非同位素标记;d5代表同位素标记)快速衍生化反应,反应条件:制备苯甲酰氯溶液(由于苯甲酰氯易挥发且容易发生水解,因此该试剂要现用现配),将苯甲酰氯加入步骤(1)的酶切反应液中,迅速混匀,常温放置30min。(2) Rapid derivatization reaction between sugar amine obtained in step (1) and d0/d5-benzoyl chloride (d0 represents non-isotopic labeling; d5 represents isotopic labeling), reaction conditions: prepare benzoyl chloride solution (because benzoyl chloride is volatile And it is prone to hydrolysis, so this reagent should be used and prepared immediately), add benzoyl chloride to the enzyme cleavage reaction solution in step (1), mix quickly, and leave at room temperature for 30min.
(3)SPE纯化:对步骤(2)的反应溶液进行纯化处理,其步骤为:①3ml去离子水清洗MCC纯化柱;②3ml平衡液(正丁醇:乙醇:水=4:1:1)对MCC进行平衡;③将800ul平衡液加入步骤(2)的聚糖反应体系中,充分混匀,上样;④ 3ml平衡液(正丁醇:乙醇:水=4:1:1)对MCC进行冲洗,脱去所有杂质;⑤1ml洗脱液(乙醇:水=1:1)对样品进行洗脱,蒸干备用。(3) SPE purification: Purify the reaction solution in step (2), the steps are: ① 3ml deionized water to wash the MCC purification column; ② 3ml balance solution (n-butanol:ethanol:water=4:1:1) to The MCC is balanced; 3. 800ul of the equilibrated solution is added to the glycan reaction system of step (2), fully mixed, and sampled; 4. 3 ml of the equilibrated solution (n-butanol:ethanol:water=4:1:1) is applied to the MCC Rinse to remove all impurities; ⑤1ml eluent (ethanol:water=1:1) to elute the sample, evaporate to dryness for later use.
(4)甲胺化反应:甲胺化处理之前,将d0-苯甲酰氯和d5-苯甲酰氯衍生的N 聚糖以1:1摩尔比进行混合,之后25ul甲胺盐酸盐溶液(用100ul二甲基亚砜溶解7mg甲胺盐酸盐,之后加入5.5ul甲基玛琳溶液)和25ul PyAOP溶液(用 100ul二甲基亚砜溶解2.6mg PyAOP)加入到干燥的混合样品中,于常温且黑暗处静置30min,SPE纯化,步骤同上。(注:如图3,在验证该方法定量能力的稳定性时,d0-苯甲酰氯和d5-苯甲酰氯衍生的标准糖蛋白聚糖以摩尔比1:1进行混合,之后进行甲胺化处理;如图4,在验证该方法在定量线性范围方面的应用时,上述d0-苯甲酰氯和d5-苯甲酰氯衍生的N聚糖以7种摩尔比进行混合,之后进行甲胺化处理;从图5可以看出该方法具有10倍的线性定量范围)。(4) methylamination reaction: before the methylamination treatment, d0-benzoyl chloride and d5-benzoyl chloride-derived N-glycans were mixed at a 1:1 molar ratio, and then 25ul of methylamine hydrochloride solution (with 100ul DMSO to dissolve 7mg methylamine hydrochloride, then add 5.5ul methylmarine solution) and 25ul PyAOP solution (dissolve 2.6mg PyAOP in 100ul DMSO) and add to the dry mixed sample. It was left standing for 30 min at room temperature and in the dark, and purified by SPE, and the steps were the same as above. (Note: As shown in Figure 3, to verify the stability of the quantitative capability of this method, d0-benzoyl chloride and d5-benzoyl chloride-derived standard glycoproteoglycans were mixed in a molar ratio of 1:1, followed by methylamination treatment; as shown in Figure 4, when verifying the application of this method in the quantitative linear range, the above-mentioned d0-benzoyl chloride and d5-benzoyl chloride-derived N-glycans were mixed in 7 molar ratios, followed by methylamination treatment ; it can be seen from Figure 5 that the method has a 10-fold linear quantitative range).
(5)MALDI-MS对聚糖样品进行检测:将步骤(4)双衍生化的N-聚糖溶于10 μL溶液(乙腈:水=1:1)中,取1.0μL该样品溶液与1.0μL DHB溶液混合后点样到384孔板上,每个点约1.0μL液体。把孔板水平静置15min以便溶剂挥发,然后通过MALDI-MS 5800(SCIEX公司)完成N-聚糖检测。(5) Detection of glycan samples by MALDI-MS: Dissolve the double-derivatized N-glycans in step (4) in 10 μL of solution (acetonitrile: water = 1:1), take 1.0 μL of the sample solution and 1.0 μL of the solution. μL of DHB solution was mixed and spotted onto a 384-well plate, with about 1.0 μL of liquid per spot. The plate was left to stand horizontally for 15 min to evaporate the solvent, and then N-glycan detection was performed by MALDI-MS 5800 (SCIEX).
基质辅助激光解吸电离质谱仪相关参数设置如下:检测模式,ReflectorPositive;激光强度(laser intensity),5200;电压倍数(detector voltagemultiplier),0.60;离子的质量范围(TOF masses),1000-5000m/z。The relevant parameters of the matrix-assisted laser desorption ionization mass spectrometer are set as follows: detection mode, ReflectorPositive; laser intensity (laser intensity), 5200; voltage multiplier (detector voltagemultiplier), 0.60; ion mass range (TOF masses), 1000-5000m/z.
(6)数据分析:MALDI-MS数据由软件Data Explorer 4.0解析;N-聚糖的结构示意图由软件GlycoWorkbench 2.1指定。(注:该方法在肿瘤标记物挖掘方面具有潜在应用价值,如图6)。(6) Data analysis: MALDI-MS data was analyzed by the software Data Explorer 4.0; the structural schematic diagram of N-glycans was specified by the software GlycoWorkbench 2.1. (Note: This method has potential application value in tumor marker mining, as shown in Figure 6).
一种基于MALDI-MS及稳定同位素标记的N聚糖快速定量分析方法的应用,该方法可用于血清聚糖分析。An application of a rapid quantitative analysis method based on MALDI-MS and stable isotope-labeled N-glycan, which can be used for serum glycan analysis.
与现有技术相比,本发明的优点为:Compared with the prior art, the advantages of the present invention are:
1、提升实验效率:采用微波辅助快速酶切,极大缩短了反应时间,使整体反应在2小时内完成,极大提高了实验效率。1. Improve experimental efficiency: The use of microwave-assisted rapid enzyme digestion greatly shortens the reaction time, so that the overall reaction can be completed within 2 hours, which greatly improves the experimental efficiency.
2、消除系统差异干扰:运用稳定同位素(d0/d5-苯甲酰氯)对N聚糖进行分析,可以在最大程度上削弱样品离子化效率和仪器响应值不同所带来的差异。2. Eliminate the interference of system differences: The use of stable isotopes (d0/d5-benzoyl chloride) to analyze N-glycans can minimize the differences in sample ionization efficiency and instrument response values.
3、低成本:该方法所采用的同位素已实现商品化且造价低廉,同时由于采用了同位素定量技术,无需再引入内标或外标物,极大降低了实验成本以及实验复杂程度。3. Low cost: The isotopes used in this method have been commercialized and have low cost. At the same time, due to the use of isotope quantification technology, there is no need to introduce internal or external standards, which greatly reduces the experimental cost and experimental complexity.
4、反应条件温和:该实验在弱碱性且常温条件下即可发生反应,且衍生效率超过99%,不会对酸性基团造成破坏。4. Mild reaction conditions: The experiment can react under weak alkaline and normal temperature conditions, and the derivatization efficiency exceeds 99%, which will not cause damage to acidic groups.
5、对中性糖和酸性糖同时进行定量分析:该方法中由于采用了甲胺化法对酸性糖进行中性化处理,对酸性基团(唾液酸)进行了有效的保护,防止其在后期质谱检测中由于源内和源后裂解所带来的干扰(注:如果没有甲胺化等中性化处理,唾液酸在质谱检测时会发生源内和源后裂解,对酸性糖结构造成永久性破坏,不仅使酸性糖定量化为泡影,还会产生许多杂质峰,对数据分析造成极大干扰)。5. Simultaneous quantitative analysis of neutral sugars and acidic sugars: In this method, since the methylamination method is used to neutralize the acidic sugars, the acidic groups (sialic acid) are effectively protected to prevent them from Interference caused by in-source and post-source cleavage in later mass spectrometry detection (Note: If there is no neutralization treatment such as methylamination, sialic acid will undergo in-source and post-source cleavage during mass spectrometry detection, causing permanent damage to the acidic sugar structure. Destruction, not only makes the quantification of acidic sugars into bubbles, but also produces many impurity peaks, which greatly interferes with data analysis).
6、提升定量能力:该方法在聚糖定量方面展现了10倍的动态线性范围,且能够对皮摩水平的聚糖进行精准分析。6. Improve quantitative ability: This method exhibits a 10-fold dynamic linear range in glycan quantification, and can accurately analyze glycans at picomolar level.
7、医学应用价值:为了体现在医学领域的价值,该方法还被用于血清聚糖分析,通过比较不同病理阶段血清聚糖的变化,以筛选出可以作为病理快速诊断的特异性标记物。7. Medical application value: In order to reflect the value in the medical field, this method is also used for serum glycan analysis. By comparing the changes of serum glycans in different pathological stages, specific markers that can be used as rapid pathological diagnosis can be screened out.
附图说明Description of drawings
图1为MALDI-MS及稳定同位素标记N聚糖快速定量分析流程图。Figure 1 is a flow chart of the rapid quantitative analysis of MALDI-MS and stable isotope-labeled N-glycans.
图2为糖胺与苯甲酰氯衍生条件优化图。Figure 2 is a diagram showing the optimization of the derivatization conditions of sugar amine and benzoyl chloride.
图3-A至图3-C为该方法在标准糖蛋白N聚糖定量分析中的应用。Figures 3-A to 3-C illustrate the application of this method in the quantitative analysis of standard glycoprotein N glycans.
图4为七种不同摩尔比定量d0/d5-苯甲酰氯衍生的核糖核酸酶B聚糖。Figure 4 quantifies d0/d5-benzoyl chloride derivatized RNase B glycans at seven different molar ratios.
图5为该方法可达到10倍的线性定量范围。Figure 5 shows the 10-fold linear quantitative range of this method.
图6为该方法在肿瘤标记物筛选方面的应用。Figure 6 shows the application of this method in tumor marker screening.
具体实施方式Detailed ways
以下是本发明的具体实施例,对本发明的技术方案做进一步作描述,但是本发明的保护范围并不限于这些实施例。凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。The following are specific embodiments of the present invention to further describe the technical solutions of the present invention, but the protection scope of the present invention is not limited to these embodiments. All changes or equivalent substitutions that do not depart from the concept of the present invention are included in the protection scope of the present invention.
实施例1Example 1
一种基于MALDI-MS及稳定同位素标记的N聚糖快速定量分析方法,该方法包括如下步骤(见图1):A method for rapid quantitative analysis of N-glycans based on MALDI-MS and stable isotope labeling, the method comprises the following steps (see Figure 1):
(1)微波辅助快速酶切:标准糖蛋白(10ug)或血清(5ul)溶解于20ul 反应溶液中(含有10mM磷酸钠、0.13%的十二烷基硫酸钠、10mM二硫苏糖醇),之后于100℃水浴中煮沸10min,加入2.4ul 10%的NP-40,混匀后再加入0.5ul PNGase F,在微波辅助条件下酶切20min(实验所用微波炉最大输出功率为700W,反应时选用最低档位),使N聚糖以糖胺形式释放。(1) Microwave-assisted rapid digestion: standard glycoprotein (10ug) or serum (5ul) was dissolved in 20ul reaction solution (containing 10mM sodium phosphate, 0.13% sodium dodecyl sulfate, 10mM dithiothreitol), Then boil in a 100°C water bath for 10min, add 2.4ul of 10% NP-40, add 0.5ul of PNGase F after mixing, and digest the enzyme for 20min under microwave-assisted conditions (the maximum output power of the microwave oven used in the experiment is 700W. lowest gear), which releases N-glycans in the form of glycosamines.
(2)步骤(1)所得糖胺与d0/d5-苯甲酰氯(d0代表非同位素标记;d5代表同位素标记)快速衍生化反应,反应条件:制备苯甲酰氯溶液(由于苯甲酰氯易挥发且容易发生水解,因此该试剂要现用现配),将苯甲酰氯加入到步骤(1) 的酶切反应液中,迅速混匀,常温放置30min。(2) Rapid derivatization reaction between sugar amine obtained in step (1) and d0/d5-benzoyl chloride (d0 represents non-isotopic labeling; d5 represents isotopic labeling), reaction conditions: prepare benzoyl chloride solution (because benzoyl chloride is volatile And it is prone to hydrolysis, so the reagent should be used and prepared immediately), add benzoyl chloride to the enzyme cleavage reaction solution in step (1), mix quickly, and leave at room temperature for 30min.
(3)SPE纯化:对步骤(2)的反应溶液进行纯化处理,其步骤为:①3ml去离子水清洗MCC纯化柱;②3ml平衡液(正丁醇:乙醇:水=4:1:1)对MCC进行平衡;③将800ul平衡液加入步骤(2)的聚糖反应体系中,充分混匀,上样;④ 3ml平衡液(正丁醇:乙醇:水=4:1:1)对MCC进行冲洗,脱去所有杂质;⑤1ml洗脱液(乙醇:水=1:1)对样品进行洗脱,蒸干备用。(3) SPE purification: Purify the reaction solution in step (2), the steps are: ① 3ml deionized water to wash the MCC purification column; ② 3ml balance solution (n-butanol:ethanol:water=4:1:1) to The MCC is balanced; 3. 800ul of the equilibrated solution is added to the glycan reaction system of step (2), fully mixed, and sampled; 4. 3 ml of the equilibrated solution (n-butanol:ethanol:water=4:1:1) is applied to the MCC Rinse to remove all impurities; ⑤1ml eluent (ethanol:water=1:1) to elute the sample, evaporate to dryness for later use.
(4)甲胺化反应:甲胺化处理之前,将d0-苯甲酰氯和d5-苯甲酰氯衍生的N 聚糖以1:1摩尔比进行混合得混合样品,之后将25ul甲胺盐酸盐溶液(用100ul 二甲基亚砜溶解7mg甲胺盐酸盐,之后加入5.5ul甲基玛琳溶液)和25ul PyAOP 溶液(用100ul二甲基亚砜溶解2.6mg PyAOP)加入到上述混合样品中,于常温且黑暗处静置30min,SPE纯化,步骤同上。(4) Methylamination reaction: before the methylamination treatment, d0-benzoyl chloride and d5-benzoyl chloride-derived N-glycans were mixed at a molar ratio of 1:1 to obtain a mixed sample, and then 25 ul of methylamine hydrochloric acid was added. Salt solution (dissolve 7mg methylamine hydrochloride in 100ul DMSO, then add 5.5ul methylmarine solution) and 25ul PyAOP solution (dissolve 2.6mg PyAOP in 100ul DMSO) were added to the above mixed sample , stand for 30 min at room temperature and in the dark, and purify by SPE, the steps are the same as above.
(5)MALDI-MS对聚糖样品进行检测:将步骤(4)双衍生化的N-聚糖溶于10 μL溶液(乙腈:水=1:1)中,取1.0μL该样品溶液与1.0μL DHB溶液混合后点样到384孔板上,每个点约1.0μL液体。把孔板水平静置15min以便溶剂挥发,然后通过MALDI-MS 5800(SCIEX公司)完成N-聚糖检测。(5) Detection of glycan samples by MALDI-MS: Dissolve the double-derivatized N-glycans in step (4) in 10 μL of solution (acetonitrile: water = 1:1), take 1.0 μL of the sample solution and 1.0 μL of the solution. μL of DHB solution was mixed and spotted onto a 384-well plate, with about 1.0 μL of liquid per spot. The plate was left to stand horizontally for 15 min to evaporate the solvent, and then N-glycan detection was performed by MALDI-MS 5800 (SCIEX).
基质辅助激光解吸电离质谱仪相关参数设置如下:检测模式,ReflectorPositive;激光强度(laser intensity),5200;电压倍数(detector voltagemultiplier),0.60;离子的质量范围(TOF masses),1000-5000m/z。The relevant parameters of the matrix-assisted laser desorption ionization mass spectrometer are set as follows: detection mode, ReflectorPositive; laser intensity (laser intensity), 5200; voltage multiplier (detector voltagemultiplier), 0.60; ion mass range (TOF masses), 1000-5000m/z.
(6)数据分析:MALDI-MS数据由软件Data Explorer 4.0解析;N-聚糖的结构示意图由软件GlycoWorkbench 2.1指定。(6) Data analysis: MALDI-MS data was analyzed by the software Data Explorer 4.0; the structural schematic diagram of N-glycans was specified by the software GlycoWorkbench 2.1.
实施例2Example 2
为了验证苯甲酰氯与糖胺的衍生化效果,对会影响衍生效率的pH、温度和反应时间进行了优化探索(结果见图2),实验中是以苯甲酰氯和Man5GlcNAc2(属于标准糖蛋白--核糖核酸酶B的五种聚糖中的一种)的衍生效率为基准进行探讨,图2-A为:反应环境pH对衍生效率的影响,可以看出当pH达到9.0时,可以达到最佳衍生效果;图2-B为:反应温度对衍生效率的影响,可以看出当温度处于 20℃,可以达到最佳衍生效果;图2-C为:反应时间对衍生效率的影响,可以看出当反应时间达到40min时,可以达到最佳衍生效果。In order to verify the derivatization effect of benzoyl chloride and sugar amine, the pH, temperature and reaction time that will affect the derivatization efficiency were optimized and explored (the results are shown in Figure 2). In the experiment, benzoyl chloride and Man5GlcNAc2 (a standard glycoprotein The derivatization efficiency of one of the five glycans of ribonuclease B) was discussed as a benchmark. Figure 2-A shows the effect of pH of the reaction environment on the derivatization efficiency. It can be seen that when the pH reaches 9.0, it can reach The best derivatization effect; Figure 2-B: the effect of reaction temperature on the derivatization efficiency, it can be seen that when the temperature is 20 °C, the best derivatization effect can be achieved; Figure 2-C: The effect of reaction time on the derivatization efficiency can be It can be seen that the best derivatization effect can be achieved when the reaction time reaches 40min.
实施例3Example 3
分别对三种标准糖蛋白--核糖核酸酶B、胎牛蛋白Fetuin和免疫球蛋白IgG 进行分析(结果见图3),图3-A为:核糖核酸酶B聚糖定量分析,当d0-苯甲酰氯和d5-苯甲酰氯衍生的N聚糖以摩尔比1:1进行混合后,可以看出该标准糖蛋白中的五种N聚糖几乎均以等高离子对形式存在(等高离子对所呈现的状态与摩尔比1:1一致);图3-B为:胎牛蛋白Fetuin聚糖定量分析,当d0-苯甲酰氯和d5-苯甲酰氯衍生的N聚糖以摩尔比1:1进行混合后,可以看出该标准糖蛋白中的五种N聚糖几乎均以等高离子对形式存在;图3-C为:免疫球蛋白IgG聚糖定量分析,当d0-苯甲酰氯和d5-苯甲酰氯衍生的N聚糖以摩尔比1:1进行混合后,可以看出该标准糖蛋白中的N聚糖几乎均以等高聚糖离子对形式存在。以上结果充分说明该方法在聚糖定量上的稳定性。Three standard glycoproteins - ribonuclease B, fetal bovine protein Fetuin and immunoglobulin IgG were analyzed respectively (the results are shown in Figure 3). Figure 3-A is: quantitative analysis of ribonuclease B glycans, when d0- After the N-glycans derived from benzoyl chloride and d5-benzoyl chloride were mixed in a molar ratio of 1:1, it could be seen that almost all of the five N-glycans in the standard glycoprotein existed in the form of equal height ion pairs (equal height). The state presented by the ion pair is consistent with the molar ratio of 1:1); Figure 3-B: Quantitative analysis of Fetuin glycans in fetal bovine protein, when d0-benzoyl chloride and d5-benzoyl chloride-derived N glycans are in a molar ratio After mixing at 1:1, it can be seen that the five N glycans in the standard glycoprotein are almost all in the form of equal ion pairs; Figure 3-C: Quantitative analysis of immunoglobulin IgG glycans, when d0-benzene After the N-glycans derived from formyl chloride and d5-benzoyl chloride were mixed in a molar ratio of 1:1, it could be seen that almost all of the N-glycans in the standard glycoprotein existed in the form of isomeric glycan ion pairs. The above results fully demonstrate the stability of this method in glycan quantification.
实施例4Example 4
为了验证该定量方法的线性动态范围,d0-苯甲酰氯和d5-苯甲酰氯衍生的核糖核酸酶B聚糖以七种不同的摩尔比进行混合(结果见图4),(A)10:1、(B)5:1、 (C)2:1、(D)1:1、(E)1:2、(F)1:5、(G)1:10,从上述结果可以看出d0-苯甲酰氯和d5-苯甲酰氯衍生的聚糖峰均以上述七种不同的比例离子对的形式展现,说明了该方法的在定量方面的线性可行性。To verify the linear dynamic range of this quantitative method, d0-benzoyl chloride and d5-benzoyl chloride derivatized RNase B glycans were mixed in seven different molar ratios (results are shown in Figure 4), (A) 10: 1. (B)5:1, (C)2:1, (D)1:1, (E)1:2, (F)1:5, (G)1:10, it can be seen from the above results The glycan peaks derived from d0-benzoyl chloride and d5-benzoyl chloride are displayed in the form of the above-mentioned seven different proportional ion pairs, indicating the linear feasibility of this method in terms of quantification.
对图4结果进行的线性统计分析,由于上述五种聚糖均以7种比例进行混合,因而每条线均呈现7个分隔点,统计学分析发现实验比值与理论比值非常接近,五种聚糖的拟合系数R值均高于0.999,说明该方法具有非常好的线性定量范围,具体结果见图5。The linear statistical analysis of the results in Figure 4 shows that since the above five glycans are mixed in seven proportions, each line presents seven separation points. Statistical analysis shows that the experimental ratio is very close to the theoretical ratio, and the five poly The R values of the fitting coefficients of sugars were all higher than 0.999, indicating that the method has a very good linear quantitative range. The specific results are shown in Figure 5.
实施例5Example 5
用d0-苯甲酰氯和d5-苯甲酰氯分别标记正常人血清聚糖和骨髓瘤早期患者血清聚糖(结果见图6),从图6-A中可以看出,大部分聚糖离子对都是等高的,说明正常人血清和骨髓瘤患者血清中的大部分聚糖在含量上没有发生太大变化,从中随机选取了几个聚糖离子对如图6-B~D,这些局部放大的图更好得说明了大部分聚糖在峰值上没有太大的变化;但是,还是有一些聚糖在这两种血清中存在一些变化的(如图6-E~G),其中图6-E~F中这两种聚糖在骨髓瘤早期患者血清中较正常人血清均发生上调,而图6-G中的这种聚糖却发生了下调,上述结果非常直观地表明了该定量方法在肿瘤标记物挖掘方面的应用价值。Normal human serum glycans and serum glycans from patients with early myeloma were labeled with d0-benzoyl chloride and d5-benzoyl chloride, respectively (the results are shown in Figure 6). It can be seen from Figure 6-A that most of the glycan ion pairs All of them are of the same height, indicating that most of the glycans in normal human serum and serum of myeloma patients have not changed much in content, and several glycan ion pairs were randomly selected from these The enlarged graph better illustrates that most of the glycans do not change much at the peak; however, there are still some glycans that show some change in the two sera (Fig. 6-E-G), where Fig. These two glycans in 6-E-F were up-regulated in the serum of patients with early myeloma compared with normal human serum, but this glycan in Fig. 6-G was down-regulated. Application value of quantitative methods in tumor marker mining.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710508392.6A CN107449650B (en) | 2017-06-28 | 2017-06-28 | Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710508392.6A CN107449650B (en) | 2017-06-28 | 2017-06-28 | Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107449650A CN107449650A (en) | 2017-12-08 |
CN107449650B true CN107449650B (en) | 2020-07-31 |
Family
ID=60488265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710508392.6A Active CN107449650B (en) | 2017-06-28 | 2017-06-28 | Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107449650B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110108780B (en) * | 2019-05-15 | 2020-06-05 | 浙江大学 | Application of 3-hydrazinobenzoic acid-derivatized glucan in MALDI-TOF-MS (matrix-assisted laser Desorption-time of flight-Mass Spectrometry) |
CN110243920B (en) * | 2019-05-29 | 2021-12-14 | 吉林大学 | A method for the detection of small molecule sugars using 2-hydrazinoquinoline as a reactive matrix in MALDI-TOF-MS |
CN112326773B (en) * | 2020-10-16 | 2024-01-12 | 华中科技大学鄂州工业技术研究院 | Method for high-throughput analysis of IgG glycopeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101657725A (en) * | 2007-04-16 | 2010-02-24 | 动量制药公司 | Use exoglycosidase that the N-glycan is characterized |
CN105308061A (en) * | 2013-04-03 | 2016-02-03 | 协会合作研究中心生物公司 | Synthesis and use of isotopically-labelled glycans |
-
2017
- 2017-06-28 CN CN201710508392.6A patent/CN107449650B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101657725A (en) * | 2007-04-16 | 2010-02-24 | 动量制药公司 | Use exoglycosidase that the N-glycan is characterized |
CN105308061A (en) * | 2013-04-03 | 2016-02-03 | 协会合作研究中心生物公司 | Synthesis and use of isotopically-labelled glycans |
Non-Patent Citations (5)
Title |
---|
Dual Modifications Strategy to Quantify Neutral and Sialylated N-Glycans Simultaneously by MALDI-MS;Hui Zhou et al.;《Analytical Chemistry》;20140425;第86卷;Abstract,第6278-6280页 Experimental Section,Fig 1 * |
MALDI-MS analysis of sialylated N-glycan linkage isomers using solid-phase two step derivatization method;Henghui Li et al.;《Analytica Chimica Acta》;20160425;第924卷;第77-85页 * |
Metallic Element Chelated Tag Labeling (MeCTL) for Quantitation of N‑Glycans in MALDI-MS;Lijun Yang et al.;《 Analytical Chemistry》;20170621;第89卷;第7470-7476页 * |
Microwave-assisted deglycosylation for rapid and sensitive analysis of N-glycans via glycosylamine derivatization;Yike Wu et al.;《Analytical and Bioanalytical Chemistry》;20170417;第409卷(第16期);第4027-4029页 * |
Quantitative Glycome Analysis of N‑Glycan Patterns in Bladder Cancer vs Normal Bladder Cells Using an Integrated Strategy;Ganglong Yang et al.;《Journal of proteome research》;20141223;第14卷;第639-653页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107449650A (en) | 2017-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Preisler et al. | Capillary Electrophoresis− Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Using a Vacuum Deposition Interface | |
Magalhaes et al. | Comparison of urine and plasma peptidome indicates selectivity in renal peptide handling | |
CN107449650B (en) | Rapid quantitative analysis method and application of N-glycans based on MALDI-MS and stable isotope labeling | |
Reid et al. | Selective identification and quantitative analysis of methionine containing peptides by charge derivatization and tandem mass spectrometry | |
Jiang et al. | A one-step preparation method of monolithic enzyme reactor for highly efficient sample preparation coupled to mass spectrometry-based proteomics studies | |
Lai et al. | Rapid monitoring assay of congenital adrenal hyperplasia with microbore high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry from dried blood spots | |
Chen et al. | Development of a hydrophilic interaction liquid chromatography coupled with matrix-assisted laser desorption/ionization-mass spectrometric imaging platform for N-glycan relative quantitation using stable-isotope labeled hydrazide reagents | |
Callesen et al. | Serum protein profiling by miniaturized solid‐phase extraction and matrix‐assisted laser desorption/ionization mass spectrometry | |
CN107271593B (en) | Target plate derivatization and MALDI-TOF-MS analysis method of reducing sugar chains | |
Ongay et al. | Isoform differentiation of intact AGP from human serum by capillary electrophoresis–mass spectrometry | |
Guo et al. | Simultaneous determination of linarin, naringenin and formononetin in rat plasma by LC‐MS/MS and its application to a pharmacokinetic study after oral administration of Bushen Guchi Pill | |
Deguchi et al. | Structural analysis of O‐glycopeptides employing negative‐and positive‐ion multi‐stage mass spectra obtained by collision‐induced and electron‐capture dissociations in linear ion trap time‐of‐flight mass spectrometry | |
Zhou et al. | Fractionation and characterization of sialyl linkage isomers of serum N‐glycans by CE–MS | |
Grundmann et al. | Fast counter-electroosmotic capillary electrophoresis–time-of-flight mass spectrometry of hyaluronan oligosaccharides | |
Ko et al. | Ultraviolet photodissociation of chromophore‐labeled oligosaccharides via reductive amination and hydrazide conjugation | |
EP2435832A1 (en) | Methods and reagents for the quantitative determination of metabolites in biological samples | |
JP7107477B2 (en) | Methods for detecting mitochondrial tRNA modifications | |
Li et al. | Analysis of urinary methylated nucleosides of patients with coronary artery disease by high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry | |
Yao et al. | Specific enrichment of peptides with N-terminal serine/threonine by a solid-phase capture-release approach for efficient proteomics analysis | |
Su et al. | A comparative study of data‐dependent acquisition and data‐independent acquisition in proteomics analysis of clinical lung cancer tissues constrained by blood contamination | |
Sandoval | Matrix‐assisted laser desorption/ionization time‐of‐flight mass analysis of peptides | |
North et al. | Minimizing cationization effects in the analysis of complex mixtures of oligosaccharides | |
Henzel et al. | Matrix‐assisted laser desorption/ionization time‐of‐flight mass analysis of peptides | |
CN103694342B (en) | Detect the polypeptide marker of people's aging | |
Taylor et al. | Efficient high-throughput discovery of large peptidic hormones and biomarkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |